Literature DB >> 22267593

Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence.

Daniel Candotti1, C Kit Lin, Dalila Belkhiri, Tasanee Sakuldamrongpanich, Subhajit Biswas, Sujen Lin, Diana Teo, Yasmin Ayob, Jean-Pierre Allain.   

Abstract

OBJECTIVE: To investigate the molecular basis of occult hepatitis B virus (HBV) infection (OBI) in Asian blood donors.
DESIGN: OBI donors from Hong Kong, Malaysia, Singapore, Taiwan and Thailand were tested for HBV serological markers, and strains were molecularly characterised.
RESULTS: Among 138 confirmed OBI carriers (median age 47 years), HBV genotypes B and C were dominant (60% and 34%, respectively) in agreement with the genotype distribution in chronically infected donors in the region. Viral load ranged between unquantifiable and 3670 IU/ml (median 11 IU/ml). Eleven per cent of OBIs showed an unusual anti-HBs-only serological profile without evidence of past vaccination for most of these individuals. Occult HBV strains showed a higher genetic diversity than strains from matched hepatitis B surface antigen (HBsAg)+ donors, irrespective of genotype. No unique genetic signature or evidence of reduced replication competence was found. Mutations in the vicinity of the pre-S2/S splice donor site were common in OBI(B) (44%) and OBI(C) (36%) strains. S regions from four OBI cases were transfected in HuH7 cells. Results showed limited HBsAg secretion and suggested that mutations disrupting the splice donor site structure may affect pre-S2/S mRNA splicing.
CONCLUSIONS: There is indirect evidence that incomplete immune control is involved in the occurrence of OBI in Asian blood donors infected with genotypes B and C as observed in Europe with genotype A2 but to a lower extent than with genotype D. A post-transcriptional mechanism may play a role in HBsAg expression in some OBIs irrespective of HBV genotype.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22267593     DOI: 10.1136/gutjnl-2011-301281

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  40 in total

1.  Specific amino acid substitutions in the S protein prevent its excretion in vitro and may contribute to occult hepatitis B virus infection.

Authors:  Subhajit Biswas; Daniel Candotti; Jean-Pierre Allain
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

Review 2.  Occult hepatitis B virus infection and blood transfusion.

Authors:  Dong Hee Seo; Dong Hee Whang; Eun Young Song; Kyou Sup Han
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  Molecular virology in transfusion medicine laboratory.

Authors:  Daniel Candotti; Jean-Pierre Allain
Journal:  Blood Transfus       Date:  2012-12-21       Impact factor: 3.443

Review 4.  Molecular mechanisms underlying HBsAg negativity in occult HBV infection.

Authors:  R A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-06-24       Impact factor: 3.267

5.  Recent and occult hepatitis B virus infections among blood donors in the United States.

Authors:  Sumathi Ramachandran; Jamel A Groves; Guo-Liang Xia; Paula Saá; Edward P Notari; Jan Drobeniuc; Amanda Poe; Natasha Khudyakov; Sarah F Schillie; Trudy V Murphy; Saleem Kamili; Chong-Gee Teo; Roger Y Dodd; Yury E Khudyakov; Susan L Stramer
Journal:  Transfusion       Date:  2018-11-30       Impact factor: 3.157

6.  Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy.

Authors:  Wai-Kay Seto; Danny Ka-Ho Wong; Thomas Sau-Yan Chan; Yu-Yan Hwang; James Fung; Kevin Sze-Hang Liu; Harinder Gill; Yuk-Fai Lam; Ka-Shing Cheung; Albert K W Lie; Ching-Lung Lai; Yok-Lam Kwong; Man-Fung Yuen
Journal:  Am J Gastroenterol       Date:  2016-09-20       Impact factor: 10.864

Review 7.  Screening and diagnosis of HBV in low-income and middle-income countries.

Authors:  Jean-Pierre Allain; Ohene Opare-Sem
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-14       Impact factor: 46.802

8.  Development of a highly sensitive bioluminescent enzyme immunoassay for hepatitis B virus surface antigen capable of detecting divergent mutants.

Authors:  Takayuki Minekawa; Shizuka Takehara; Masaharu Takahashi; Hiroaki Okamoto
Journal:  Clin Vaccine Immunol       Date:  2013-06-12

9.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

10.  Occult hepatitis B virus infection among Egyptian blood donors.

Authors:  Zeinab N Said; Manal H El Sayed; Iman I Salama; Enas K Aboel-Magd; Magda H Mahmoud; Maged El Setouhy; Faten Mouftah; Manal B Azzab; Heidi Goubran; Amal Bassili; Gamal E Esmat
Journal:  World J Hepatol       Date:  2013-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.